Nothing Special   »   [go: up one dir, main page]

WO2010137032A3 - Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts - Google Patents

Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts Download PDF

Info

Publication number
WO2010137032A3
WO2010137032A3 PCT/IN2010/000301 IN2010000301W WO2010137032A3 WO 2010137032 A3 WO2010137032 A3 WO 2010137032A3 IN 2010000301 W IN2010000301 W IN 2010000301W WO 2010137032 A3 WO2010137032 A3 WO 2010137032A3
Authority
WO
WIPO (PCT)
Prior art keywords
elvitegravir
polymorphic forms
pharmaceutically acceptable
acceptable salts
novel polymorphic
Prior art date
Application number
PCT/IN2010/000301
Other languages
French (fr)
Other versions
WO2010137032A2 (en
Inventor
Siva Rama Prasad Vellanki
Vilas Nathu Dhake
Satyanarayana Ravi
Ravi Nuchu
Ravindra Puliyala
Original Assignee
Matrix Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Laboratories Ltd. filed Critical Matrix Laboratories Ltd.
Publication of WO2010137032A2 publication Critical patent/WO2010137032A2/en
Publication of WO2010137032A3 publication Critical patent/WO2010137032A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to amorphous Elvitegravir, amorphous Elvitegravir sodium, crystalline Elvitegravir sodium and processes for the preparation thereof. The present invention also relates to novel processes for the preparation of Elvitegravir polymorphic forms Il & III.
PCT/IN2010/000301 2009-05-14 2010-05-11 Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts WO2010137032A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1114CH2009 2009-05-14
IN1114/CHE/2009 2009-05-14

Publications (2)

Publication Number Publication Date
WO2010137032A2 WO2010137032A2 (en) 2010-12-02
WO2010137032A3 true WO2010137032A3 (en) 2011-09-15

Family

ID=43014237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000301 WO2010137032A2 (en) 2009-05-14 2010-05-11 Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts

Country Status (1)

Country Link
WO (1) WO2010137032A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102212032B (en) * 2011-04-20 2013-07-31 复旦大学 5-hyroxyquinolone derivatives, and preparation method and application thereof
US20150141457A1 (en) * 2012-05-21 2015-05-21 Hetero Research Foundation Elvitegravir solid dispersion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1564210A1 (en) * 2002-11-20 2005-08-17 Japan Tobacco Inc. 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
WO2005113508A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Stable crystal of 4-oxoquinoline compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1564210A1 (en) * 2002-11-20 2005-08-17 Japan Tobacco Inc. 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
WO2005113508A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Stable crystal of 4-oxoquinoline compound

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BYRN ET AL.: "PHARMACEUTICAL SOLIDS: A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS", PHARMACEUTICAL RESEARCH, vol. 12, no. 7, 1 July 1995 (1995-07-01), pages 945 - 954, XP000996386, ISSN: 0724-8741, DOI: 10.1023/A:1016241927429 *
HANCOCK ET AL.: "CHARACTERISTICS AND SIGNIFICANCE OF THE AMORPHOUS STATE IN PHARMACEUTICAL SYSTEMS", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 86, no. 1, 1 January 1997 (1997-01-01), pages 1 - 12, XP000929450, ISSN: 0022-3549, DOI: 10.1021/JS9601896 *
YU: "AMORPHOUS PHARMACEUTICAL SOLIDS: PREPARATION, CHARACTERIZATION AND STABILIZATION", ADVANCED DRUG DELIVERY REVIEWS, vol. 48, no. 1, 16 May 2001 (2001-05-16), pages 27 - 42, XP009065056, ISSN: 0169-409X, DOI: 10.1016/S0169-409X(01)00098-9 *

Also Published As

Publication number Publication date
WO2010137032A2 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
WO2010089770A3 (en) Processes for preparing pitavas tatin, intermediates and pharmaceutically acceptable salts thereof
WO2009066326A3 (en) Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
WO2011048604A3 (en) Processes for the preparation of darunavir and the amorphous form thereof
WO2010139981A3 (en) Processes for preparing crystalline forms of dasatinib
WO2010092090A3 (en) Novel salts of sitagliptin
WO2010001257A3 (en) Novel solid state forms of laquinimod and its sodium salt
WO2011042918A3 (en) Improved processes for preparing prasugrel and pharmaceutically acceptable salts thereof
WO2011022596A3 (en) Preparation of bazedoxifene and its salts
WO2014041487A3 (en) Enzalutamide polymorphic forms and its preparation
WO2011060213A3 (en) Preparation of sitagliptin and salts thereof
IL220211A0 (en) Process for the preparation of 1-alkyl-/1-aryl-5-pyrazolecarboxylic acid derivatives
WO2011024192A3 (en) Novel polymorphs of raltegravir
WO2010140765A3 (en) Novel method for preparing rosuvastatin, intermediate compounds useful for preparing same, and method for preparing same
WO2012015999A3 (en) Process for the preparation of imatinib mesylate
WO2011025932A3 (en) Preparation of sitagliptin and salts thereof
WO2011079193A3 (en) Preparation of bendamustine and its salts
WO2010070677A3 (en) A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
EP2216333A3 (en) Crystalline forms of Dexlansoprazole
WO2010123545A3 (en) Angiogenesis inhibitors
IN2012DN04868A (en)
WO2010129636A3 (en) Lenalidomide polymorph
WO2011004387A3 (en) Process for the preparation of dexlansoprazole polymorphic forms
WO2011023954A3 (en) Polymorphic forms of manidipine
WO2011018771A3 (en) Process for the preparation of valganciclovir hydrochloride

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10747953

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10747953

Country of ref document: EP

Kind code of ref document: A2